

Phosphagenics Begins Its Animal Health & Nutrition Program

- ***Animal Health and Nutrition business achieves key milestone with initiation of a TPM[®] feed efficiency trial in weaner pigs***
- ***First in a series of planned trials to measure efficacy of TPM[®] in animal feed across multiple species***
- ***Study to assess live weight gain and feed efficiency***
- ***Study results expected by end of 2015***

28 September 2015, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to announce it has reached a key milestone in the development of its Animal Health and Nutrition business with the initiation of the first of its feed efficiency trials utilising its proprietary ingredient, TPM[®]. The trial will assess TPM[®] as a feed additive for weaner (young) pigs, measuring live weight gain and feed efficiency amongst other key production endpoints.

The study, which is being conducted at a commercial pig integrator in Australia, will use a large number of weaner pigs. It will assess benefits of a range of TPM[®] dose treatments and will compare the effects to groups receiving standard Vitamin E (dl-alpha-tocopherol acetate) in low to high doses in “standard” rations. Data generated from this trial will be used to inform further trials and provide information necessary to assist prospective commercial partners in assessing the value of TPM[®] and its potential applications in livestock.

General Manager of Phosphagenics’ Animal Health and Nutrition Business, Dr Roksan Libinaki, said: “We believe that TPM[®] has applications well beyond simply the antioxidant properties of Vitamin E. Weaner pigs are an ideal model to assess these potential effects as they routinely experience significant metabolic stresses which can be costly to the industry. The study program has been designed with assistance from a group of experienced international animal health and animal nutrition experts and we believe positive results will attract the attention of the major global animal nutrition players. While this current trial is in pigs, we believe the data will be indicative for multiple species. Studies are already being planned for 2016 to investigate similar endpoints in a number of different species.”

Phosphagenics’ Chief Executive Officer, Dr Ross Murdoch, said “It is very pleasing to be able to announce the start of this significant trial so soon after the creation of the Business unit. This is a significant milestone for Phosphagenics and emphasises our commitment to unlock shareholder value in the short term. This is the first of a number of near-term trials we are planning to initiate in the animal health and animal nutrition space over the next 12 months. Animal Health and animal nutrition is a very appealing target market for Phosphagenics - we have a product with great potential, the cost and

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168

PO Box 1415, Clayton South MDC VIC 3169 Australia

Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151

www.phosphagenics.com Email: info@phosphagenics.com

duration of initial proof of concept studies are relatively modest, and the commercial upside could be very significant. It is already apparent that key global players are actively looking for an efficacious product in this space and therefore successful trial results have the potential to quickly lead to favourable commercial outcomes for the Company.”

Results for the primary live weight gain and feed efficiency end-points are anticipated prior to the end of the year. This study will be followed by a study on older grower/finisher pigs. Both studies have been designed and appropriately powered to enable publication in peer-reviewed journals.

Enquiries

David Segal
Phosphagenics Limited
+61 3 9565 1119

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

About Phosphagenics

Phosphagenics Limited is a drug delivery company that is commercialising various products within the pharmaceutical, cosmetics and animal health sectors, using its proprietary drug delivery system called TPM[®] (Targeted Penetration Matrix). TPM[®] is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. The lead products advancing through clinical trials are oxymorphone and oxycodone patches for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

Inherent Risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology.

Forward-looking Statements

Certain statements in this announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services.

www.phosphagenics.com